

From: [redacted]@sanidad.gob.es
Sent: jeudi 12 août 2021 18:38
To: SANTE C3 HSC
Cc: [redacted]@sanidad.gob.es
Subject: RE: HSC questions: Heterologous vaccination and 3rd booster vaccination – vaccination plans and current state of play

Thank you very much.

We will send the survey again as soon as possible.

Best regards
[redacted]

De: SANTE-C3-HSC@ec.europa.eu [<mailto:SANTE-C3-HSC@ec.europa.eu>]

Enviado el: jueves, 12 de agosto de 2021 18:10

Para: [redacted]

CC: Alertas CCAES; SANTE-C3-HSC@ec.europa.eu

Asunto: RE: HSC questions: Heterologous vaccination and 3rd booster vaccination – vaccination plans and current state of play

Dear [redacted],

Thank you for your message. Indeed we overlooked your email, please accept our apologies about that. Spain's information are included in the PDF that we will circulate tomorrow to the HSC members.

However, during yesterday's HSC meeting, you said that Spain sent replies to the survey "Acceptance of vaccines for travel purposes". We cannot see your answers, they did not reach us. May we please ask you to submit your replies again? In case you would encounter any technical issues, please do not hesitate to let us know and we will provide help.

Thank you in advance,

Kind regards,
HSC Secretariat

From: [redacted]@sanidad.gob.es <[redacted]@sanidad.gob.es>

Sent: Wednesday, August 11, 2021 11:45 AM

To: SANTE C3 HSC <SANTE-C3-HSC@ec.europa.eu>

Cc: [redacted]@sanidad.gob.es

Subject: RE: HSC questions: Heterologous vaccination and 3rd booster vaccination – vaccination plans and current state of play

I see in the presentation that this information sent on time by Spain is not included in the results presented
[redacted]

De: [REDACTED]

Enviado el: martes, 10 de agosto de 2021 10:39

Para: 'SANTE-C3-HSC@ec.europa.eu'

CC: [REDACTED]

Asunto: RE: HSC questions: Heterologous vaccination and 3rd booster vaccination – vaccination plans and current state of play

Dear Secretariat,

Please, find the answers for Spain in your own text in CAPITALS.

Best regards

[REDACTED]
HSC
SPAIN

De: SANTE-C3-HSC@ec.europa.eu [<mailto:SANTE-C3-HSC@ec.europa.eu>]

Enviado el: viernes, 06 de agosto de 2021 14:18

Para: SANTE-C3-HSC@ec.europa.eu

Asunto: HSC questions: Heterologous vaccination and 3rd booster vaccination – vaccination plans and current state of play

Dear Members of the Health Security Committee,
Dear Colleagues,

In the HSC meeting on 28 July 2021, we have presented the ECDC evidence summary on partial vaccination, vaccination of previously infected individuals and heterologous vaccination ('mix and match'). We also exchanged MS views on that topic.

Since that, we have seen rapid developments in Member States in their approaches to (1) heterologous vaccination ('mix and match') and Vaccine dose scheduling ('boosters', meaning: 3rd dose for 2-dose schedule, 2nd dose for 1-dose schedule).

Since this topic is especially pertinent and in order to prepare for the next HSC meeting with an update on these 2 topics, we would be interested in your written feedback to the below questions (reply back to this email).

Please send us your input on the following:

- 1 Is your country currently using heterologous vaccination schedules ('mix and match')?
 - a. Yes/No. **YES**
 - b. If yes, which combinations of vaccines are part of this schedule? **FOR UNDER 60 YEARS OLD, THOSE WHO RECEIVED A FIRST DOSE OF ASTRA-ZENECA ARE RECEIVING A SECOND DOSE OF AN VACCINE, EITHER PFIZER OR MODERNA.**
 - c. If yes, for which reasoning are heterologous vaccination schedules used in your country? **MAIN REASON IS HIGHER RATE OF SEVERE SIDE EFFECTS OF A-Z VACCINES AMONG UNDER 60 YEARS OLD**
 - d. If no, please provide information, for which reasons your country is not using heterologous vaccination schedules?

- 2 Is your country currently administering additional Vaccine doses ('boosters', meaning: 3rd dose for 2-dose schedule, 2nd dose for 1-dose schedule)?
- a. Yes/No. **NO**
 - b. If yes, for which population groups?
 - c. If yes, which time schedule between the original full vaccination schedule and the additional booster do you use?
 - d. If yes, are you combining additional vaccine doses (boosters) with heterologous vaccines schedules ('mix and match')?
 - e. If no, has your country plans to administer additional vaccine doses in the near future (eg. autumn season, based on which criteria)? **DECISION IS NOT MADE YET**
 - f. If no, what are the reasons for not using additional vaccine doses currently?
ALTHOUGH THERE IS NOT MUCH, CURRENT EVIDENCE SHOWS A LASTING IMMUNE RESPONSE AFTER NATURAL INFECTION AND PROBABLY AFTER VACCINATION. FURTHER STUDIES ARE NEEDED FOR MAKING AN INFORMED AND EVIDENCE BASED DECISION. EVOLUTION OF THE OUTBREAK AMONG VACCINATED SO FAR IS BEHAVING AS EXPECTED ACCORDING TO AVAILBLE EFFECTIVNESS DATA AND TRANSMISSION LEVELS IN SPAIN, THEREFORE DECISION DOES NOT NEED TO BE MADE YET AND WE CAN STILL WAIT FOR FURTHER EVIDENCE ABOUT THE NEED OR NOT OF A BOOSTER ARISING IN COMING WEEKS.
- 3 Do you have any other remark on heterologous vaccination schedules ('mix and match') and/or on additional Vaccine doses (3rd dose for 2-dose schedule, 2nd dose for 1-dose schedule)? **SCARSE EVIDENCE AVAILBLE SO FAR POINTS AT A BETTER IMMUNE RESPONSE AFTER HETEROLOGUS VACCINATION ANDTHAT IMMUNITY COULD COVER MORE VARIANTS THAN HOMOLOGOUS VACCINATION. IN ANY CASE IT IS APPLICABLE TO THOSE WHO RECEIVED A FIRST DOSE OF A-Z.**

We would appreciate it if you can send us your input **before Tuesday, 10 August cob.**

As announced in the last meeting, this topic will be subject to a future NITAG/HSC Meeting where we will further discuss it.

We will also share the Member States' state of play in the next HSC Meeting on Wednesday, 11 August.

Thank you in advance,

Kind regards,
HSC Secretariat

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.